Label: ZEVTERA- ceftobiprole medocaril sodium injection, powder, for solution

  • NDC Code(s): 84312-001-01, 84312-001-10
  • Packager: Basilea Pharmaceutica International AG, Allschwil
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated June 19, 2024

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use ZEVTERA safely and effectively. See full prescribing information for ZEVTERA. ZEVTERA (ceftobiprole medocaril sodium for ...
  • Table of Contents
    Table of Contents
  • 1 INDICATIONS AND USAGE
    1.1 Staphylococcus aureus Bloodstream Infection (Bacteremia) ZEVTERA is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infection (bacteremia) (SAB) ...
  • 2 DOSAGE AND ADMINISTRATION
    2.1 Recommended Dosage and Administration for SAB, ABSSSI and CABP in Adult Patients - The recommended dosage of ZEVTERA for the treatment of adult patients with SAB, ABSSSI and CABP is ...
  • 3 DOSAGE FORMS AND STRENGTHS
    ZEVTERA (ceftobiprole medocaril sodium for injection) is available in a single-dose vial as a white, yellowish to slightly brownish, cake to broken cake or powder containing 667 mg of ceftobiprole ...
  • 4 CONTRAINDICATIONS
    ZEVTERA is contraindicated in patients with a known history of severe hypersensitivity to ZEVTERA, or to other members of the cephalosporin class [see Warnings and Precautions (5.2)].
  • 5 WARNINGS AND PRECAUTIONS
    5.1 Increased Mortality with Unapproved Use in Ventilator-Associated Bacterial Pneumonia Patients - In Trial 4, an increase in mortality was seen in the subgroup of patients with ...
  • 6 ADVERSE REACTIONS
    The following adverse reactions are discussed in greater detail in the Warnings and Precautions section: Increased Mortality in Ventilator-Associated Bacterial Pneumonia Patients [see Warnings ...
  • 7 DRUG INTERACTIONS
    7.1 Organic Anion Transporting Polypeptide 1B1/1B3 (OATP1B1/OATP1B3) Substrates - ZEVTERA may increase the plasma concentrations of OATP1B1 and OATP1B3 substrates. Concomitant administration is ...
  • 8 USE IN SPECIFIC POPULATIONS
    8.1 Pregnancy - Risk Summary - There are no available data with use of ZEVTERA in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse ...
  • 10 OVERDOSAGE
    There is no information on clinical signs and symptoms associated with an overdose of ZEVTERA. For patients who receive doses greater than the recommended dosage regimen and have unexpected ...
  • 11 DESCRIPTION
    ZEVTERA (ceftobiprole medocaril sodium for injection) contains sodium salt of ceftobiprole medocaril, a, semisynthetic, cephalosporin antibacterial, for intravenous use. Chemically, ceftobiprole ...
  • 12 CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action - ZEVTERA is an antibacterial drug [see Microbiology (12.4)] 12.2 Pharmacodynamics - Ceftobiprole exposure-response relationships and the time course of ...
  • 13 NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - Carcinogenesis - No animal studies have been performed to evaluate the carcinogenic potential of ZEVTERA as none were ...
  • 14 CLINICAL STUDIES
    14.1 Staphylococcus aureus Bloodstream Infection (Bacteremia) Adult Patients - Trial design - The efficacy of ZEVTERA in the treatment of adult patients with SAB, including right-sided ...
  • 16 HOW SUPPLIED/STORAGE AND HANDLING
    16.1 How Supplied - ZEVTERA (ceftobiprole medocaril sodium for injection), a white, yellowish to slightly brownish sterile powder for reconstitution, supplied in a single-dose clear glass vial ...
  • 17 PATIENT COUNSELING INFORMATION
    Serious Allergic Reactions - Advise patients (or caregiver) that hypersensitivity reactions were reported with the use of ZEVTERA and that serious and occasionally fatal serious allergic ...
  • Principal Display Panel – 667 mg Carton Label
    NDC# 84312-001-10 - Rx Only - 10 single-dose vials - ZEVTERA® 667 mg/vial* (ceftobiprole medocaril sodium for injection) *equivalent to 500 mg ceftobiprole - For intravenous use ...
  • Principal Display Panel – 667 mg Vial Label
    NDC# 84312-001-01 - Rx Only - ZEVTERA® 667 mg/vial* (ceftobiprole medocaril sodium for injection) *equivalent to 500 mg ceftobiprole. Single-dose vials for - intravenous infusion. See prescribing ...
  • INGREDIENTS AND APPEARANCE
    Product Information